Cabaletta Bio IncCABA
Price$1.89

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$181.3MTTM through 30 Jun 2026
Free Cash Flow -$154.2MTTM through 30 Jun 2026

Margins

Current

Returns

-42.1%ROE
-96.5%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio2.95x
Net Debt-$116.6Mnet cash position
Cash & Equivalents$225.1M

Quality Metrics

Altman Z-Score0.69
Piotroski F-Score4 / 9
Earnings-Beat Rate50.0%

Multi-Year Trend

Diluted EPS-$1.38TTM
'22'23
FY2023: $-57.94

Dividend

No dividend

Capital Allocation

R&D Spend$157.8M

Segment Performance

SegmentRevenueYoYOutlook
Immunotherapy Development$0
View details

Advancing Phase 1/2 RESET trials for rese-cel across multiple autoimmune indications.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.